Comparison of two cancer vaccines targeting tyrosinase: Plasmid DNA and recombinant alphavirus replicon particles

Clinical Cancer Research

Volumn 11, Issue 22, 2005, Pages 8114-8121

  Goldberg, Stacie M ^a   Bartido, Shirley M ^a   Gardner, Jason P ^b   Guevara Patiñio, José A ^a   Montgomery, Stephanie C ^a   Perales, Miguel Angel ^a   Maughan, Maureen F ^c   Dempsey, JoAnn ^c   Donovan, Gerald P ^b   Olson, William C ^a   Houghton, Alan N ^b   Wolchok, Jedd D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b A Subsidiary of Lantheus Holdings   (United States)

^c AlphaVax Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DIFFERENTIATION ANTIGEN; DNA VACCINE; EPITOPE; MELANOMA ANTIGEN; MONOPHENOL MONOOXYGENASE; PLASMID DNA; PRIMER DNA; TUMOR ANTIGEN; TYROSINASE RELATED PROTEIN 1; TYROSINASE RELATED PROTEIN 2; VIRUS DNA; VIRUS VECTOR;

ALPHA VIRUS; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; DNA BINDING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IN VIVO STUDY; PRIORITY JOURNAL; REPLICON; TUMOR GROWTH; TUMOR REJECTION; VACCINATION; VIRUS LIKE REPLICON; VIRUS PARTICLE;

ALPHAVIRUS; AMINO ACID SEQUENCE; ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; DNA, RECOMBINANT; HUMANS; IMMUNIZATION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MONOPHENOL MONOOXYGENASE; PLASMIDS; REPLICON; SURVIVAL ANALYSIS;

EID: 28144464487     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1410     Document Type: Article

References (50)

1. Houghton AN. Cancer antigens: immune recognition of self and altered self. J Exp Med 1994;180:1-4.
2. Bobbins PF, Kawakami Y. Human tumor antigens recognized by T cells. Curr Opin Immunol 1996;8: 628-36.
3. Houghton AN, Eisinger M, Albino AP, Cairncross JG, Old LJ. Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J Exp Med 1982;156:1755-66.
4. Vijayasaradhi S, Bouchard B, Houghton AN. The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J Exp Med 1990;171:1375-80.
5. Brichard V, Van Pel A, Wolfel T, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993;178:489-95.
6. Bakker ABH, Schreurs MWJ, de Boer AJ, et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 1994;179:1005-9.
7. Naftzger C, Takechi Y Kohda H, Hara I, Vijayasaradhi S, Houghton AN. Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc Natl Acad Sci U S A 1996;93:14809-14.
8. Weber LW, Bowne WB, Wolchok JD, et al. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest 1998;102: 1258-64.
9. Bowne WB, Srinivasan R, Wolchok JD, et al. Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med 1999;190:1717-22.
10. Hawkins WG, Gold JS, Dyall R, et al. Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. Surgery 2000; 128:273-80.
11. Houghton AN, Gold JS, Blachere NE, Immunity against cancer: lessons learned from melanoma. Curr Opin Immunol 2001;13:134-40.
12. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and Interferon γ. Proc Natl Acad Sci U S A 1996; 93:2879-83.
13. Doolan DL, Hoffman SL. DNA-based vaccines against malaria: status and promise of the multi-stage malaria DNA vaccine operation. Int J Parasitol 2001;31: 753-62.
14. Hoffman SL, Doolan DL, Sedegah M, et al. Toward clinical trials of DNA vaccines against malaria. Immunol Cell Biol 1997;75:376-81.
15. Overwijk WW, Lee DS, Surman DR, et al. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci US A 1999;96:2982-7.
16. Perricone MA, Claussen KA, Smith KA, et al. Immunogene therapy for murine melanoma using recombinant adenoviral vectors expressing melanoma-associated antigens. Mol Ther 2000;1:275-84.
17. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000;408:605-9.
18. + Tcell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 1998;4:397-402.
19. Ramshaw IA, Ramsay AJ. The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today 2000;21:163-5.
20. Irvine KR, Chamberlain RS, Shulman EP, Surman DR, Rosenberg SA, Restifo NP. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J Natl Cancer Inst 1997;89:1595-601.
21. Ramsay AJ, Leong KH, Ramshaw IA. DNA vaccination against virus infection and enhancement of antiviral immunity following consecutive immunization with DNA and viral vectors. Immunol Cell Biol 1997;75: 382-8.
22. + T cell responses induced by recombinant influenza and vaccinia viruses. Cell Immunol 1996;173:96-107.
23. Rayner JO, Dryga SA, Kamrud KI. Alphavirus vectors and vaccination. Rev Med Virol 2002;12:279-96.
24. Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE, Smith JF. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 1997;239:389-401.
25. Davis NL, Caley IJ, Brown KW, et al. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. J Virol 2000;74:371-8.
26. Nelson EL, Prieto D, Alexander TG, et al. Venezuelan equine encephalitis replicon immunization overcomes intrinsic tolerance and elicits effective anti-tumor immunity to the 'self tumor-associated antigen, neu in a rat mammary tumor model. Breast Cancer Res Treat 2003;82:169-83.
27. Colella TA, Bullock TN, Russell LB, et al. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J Exp Med 2000;191:1221-32.
28. Bouchard B, Vijayasaradhi S, Houghton AN. Production and characterization of antibodies against human tyrosinase. J Invest Dermatol 1994;102: 291-5.
29. Bergman PJ, Mcknight J, Novosad A, et al. Long term survival of dogs with advanced malignant melanoma following DNAvaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 2003; 9:1284-90.
30. Xu Y, Bartido S, Setaluri V, Qin J, Yang G, Houghton AN. Diverse roles of conserved asparagine-linked glycan sites on tyrosinase family glycoproteins. Exp Cell Res 2001;267:115-25.
31. Mackett M, Smith GL, Moss B. Vaccinia virus: a select eukaryotic cloning and expression vector. Proc Natl Acad Sci U S A 1982;79:7415-9.
32. Falkner FG, Chakrabarti S, Moss B. pUV I: a new vaccinia virus insertion and expression vector. Nucleic Acids Res 1987;15:7192.
33. Winder A, Kobayashi T, Tsukamoto K, et al. Thetyrosinase gene family-interactions of melanogenic proteins to regulate melanogenesis. Cell Mol Biol Res 1994;40: 613-26.
34. Ross HM, Weber LW, Wang S, et al. Priming for T-cell-mediated rejection of established tumors by cutaneous DNA immunization. Clin Cancer Res 1997;3: 2191-6.
35. Parker SE, Vahlsing HL, Serfilippi LM, et al. Cancer gene therapy using plasmid DNA: safety evaluation in rodents and non-human primates. Hum Gene Ther 1995;6:575-90.
36. + T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. Clin Cancer Res 1997;3:221-6.
37. + T lymphocytes secreting tumor necrosis factor a in response to HLA-A2.1-binding melanoma and viral peptide antigens. J Immunol Methods 1996;191:131-42.
38. Wolchok JD, Gregor PD, Nordquist LT, Slovin SF, Scher HI. DNA vaccines: an active immunization strategy for prostate cancer. Semin Oncol 2003; 30:659-66.
39. Leitner WW, Hwang LN, deVeer MJ, et al. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med 2003;9:33-9.
40. Wang X, Wang JP, Maughan MF, Lachman LB. Alphavirus replicon particles containing the gene for HER2/neu inhibit breast cancer growth and tumorigenesis. Breast Cancer Res 2005;7:R145-55.
41. + T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma. Clin Cancer Res 2005; 11:370-9.
42. Gold JS, Ferrone CR, Guevara-Patino JA, et al. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J Immunol 2003;170: 5188-94.
43. Yu Z, Theoret MR, Touloukian CE, et al. Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance. J Clin Invest 2004;114:551-9.
44. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 2001;413: 732-8.
45. Fayzulin R, Frolov I. Changes of the secondary structure of the 5′ end of the Sindbis virus genome inhibit virus growth in mosquito cells and lead to accumulation of adaptive mutations. J Virol 2004;78: 4953-64.
46. Yewdell JW, Anton LC, Bennink JR. Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? J Immunol 1996; 157:1823-6.
47. Boon T, Van Pel A. T cell-recognized antigenic peptides derived from the cellular genome are not protein degradation products but can be generated directly by transcription and translation of short subgenic regions. A hypothesis. Immunogenetics 1989; 29:75-9.
48. Tevethia SS, Tevethia MJ, Lewis AJ, Reddy VB, Weissman SM. Biology of simian virus 40 (SV40) transplantation antigen (TrAg). IX. Analysis of TrAg in mouse cells synthesizing truncated SV40 large T antigen. Virology 1983;128:319-30.
49. Ostankovitch M, Robila V, Engelhard VH. Regulated folding of tyrosinase in the endoplasmic reticulum demonstrates that misfolded full-length proteins are efficient substrates for class I processing and presentation. J Immunol 2005;174:2544-51.
50. Berglund P, Fleeton MN, Smerdou C, Liljestrom P Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice. Vaccine 1999;17:497-507.